PMAIP1 and non-small cell lung carcinoma: Ma [16] reported that arenobufagin has anticancer influences on several non-small-cell lung cancer (NSCLC) cells through activation of Noxa (the pro-apoptosis protein)-related signaling pathways and promotes apoptotic cell death in human NSCLC cells.